Scopus by Title (Ref)

Altered Expression of NK Receptors in Racially/Ethnically Diverse and Risk-of-Relapse Pediatric Acute Lymphoblastic Leukemia Patients

Biomedicines

June 2025

Mathew S.

Open Access

Clinical efficacy analysis of the SCCLG-ALL-2016 protocol for the treatment of pediatric B-ALL with CD20+

China Tropical Medicine

May 2024

Qiu J.

Significance of CD34-Positive Cells in Children with B-Cell Acute Lymphoblastic Leukemia: A Case-Control Study

Iranian Journal of Pediatric Hematology and Oncology

2024

Naderisorki M.

Open Access

Baseline characteristics of a nationwide cohort of pediatric patients with acute leukemias of down syndrome

Journal of B U on

2021

Sas V.

Anticancer tendency of aflatoxin B1 in 4T1 breast cancer cell line

Gene Reports

September 2019

Mousazadeh R.

Effects of Rituximab on JAK-STAT and NF-κB signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia

Turkish Journal of Biochemistry

2019

Dalmızrak A.

Open Access

Anticancer potential of Ferula hezarlalehzarica Y. Ajani fraction in Raji lymphoma cell line: induction of apoptosis, cell cycle arrest, and changes in mitochondrial membrane potential

Daru Journal of Pharmaceutical Sciences

1 December 2018

Asemani Y.

Open Access

Prognostic Value of CD95, Active Caspase-3, and Bcl-2 Expression in Adult Patients with De Novo Acute Lymphoblastic Leukemia

Archives of Medical Research

January 2018

Montiel-Cervantes L.

Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM)

Cancer Biomarkers

2017

Xu Z.H.

Differential expression and interaction of p-catenin/ICAT proteins in NSC67657 induced monocytic differentiation of HL60 cells

Chinese Pharmacological Bulletin

November 2015

Wang W.J.

Knockdown of WISP1 inhibit proliferation and induce apoptosis in ALL Jurkat cells

International Journal of Clinical and Experimental Pathology

2015

Zhang X.